A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Trial Profile

A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Panobinostat (Primary) ; Rituximab (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
    • 10 May 2016 Results analyzing response to panobinostat treatment in a subset of patients along with biomarker analysis published in the Blood.
    • 08 Dec 2015 Results of biomarker analysis presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top